ABOUT US

Our Strategy

Saniona Icon blue

Saniona’s focus is on the discovery, development and delivery of proprietary product candidates for the treatment of rare diseases with high unmet medical need.

INVESTMENT RATIONALE

1. Tesomet: Phase 2b trials for two rare disorders voluntarily paused, subject to additional funding

Hypothalamic obesity (HO) – Impacts <65,000 in US and Europe; no approved treatments

Prader-Willi syndrome (PWS) – Impacts < 84,000 U.S. and Europe; no treatments for hyperphagia

2. Proprietary ion-channel drug discovery engine driving pipeline

SAN711: For rare neuropathic disorders, in Phase 1

SAN903: For rare inflammatory/fibrotic disorders (e.g. IPF), in preclinical

Library: 20,000 proprietary ion channel modifiers

3. Validation from multiple strategic partnerships
Medix logo Boehringer Ingelheim logo
Medix:
Tesofensine for obesity
Novartis:
CAD-1883 for movement disorders
Boehringer Ingelheim:
Novel target for schizophrenia
3. Validation from multiple strategic partnerships

Medix logo
Medix:
Tesofensine for obesity

 


Novartis:
CAD-1883 for movement disorders

 

Boehringer Ingelheim logo
Boehringer Ingelheim:
Novel target for schizophrenia

Why rare diseases?

We made the strategic decision to focus on rare diseases because of the tremendous unmet need: there are an estimated 7,000 rare diseases, and less than 10% have FDA-approved treatments. Additionally, clinical trials and regulatory reviews of medicines for rare diseases can potentially require less time and/or less financial investment than in more common disorders, and the commercial infrastructure required to serve rare patient populations is generally smaller, making rare diseases better aligned with Saniona’s capabilities.